Ruby Fill

Jump to

Jubilant Life up 5%, Fitch sees earnings boost from radiopharma

Fitch Ratings says it expects Jubilant Pharma's credit profile to benefit from new long-term contracts for its radiopharma business with leading US distributors. It assigned BB- rating with stable to the company.
Jubilant Life Sciences arm gets US FDA nod for coronary drug

Jubilant Life Sciences today said its wholly-owned subsidiary has received approval from the US health regulator for RUBY-FILL -- Rubidium 82 generator and elution system -- used in diagnosis of coronary artery disease in the US market.
Jubilant Life hits new high, up 10% on USFDA nod for Ruby-Fill

Jubilant Life Sciences shares touched a record high of Rs 676.10, up 10 percent intraday Monday after approval from the US health regulator for Ruby-Fill.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Ruby Fill

Jubilant Life up 5%, Fitch sees earnings boost from radiopharma

Jubilant Life Sciences arm gets US FDA nod for coronary drug

Jubilant Life hits new high, up 10% on USFDA nod for Ruby-Fill